CompletedNCT05859698
Patient and clinician outcomes with valbenazine treatment
About this title
Read the official source — NCT05859698Medication studyAges 18+United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Bryant and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: May 9, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 59
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT05859698
- Official title
Show the full official title
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bryant · Anaheim · Orange
15 more locations
- Torrance
- Bonita Springs
- Miami
- Miami Lakes
- Okeechobee
- Tampa
- Atlanta
- Augusta
- Marietta
- Lincoln
- Beechwood
- Oklahoma City
- DeSoto
- El Paso
- Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Did this study involve medication?
Yes. The study involved medication, including Valbenazine.
Who was this study for?
Listed age limits: from 18 years.
